Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.59 |
| ▸ | DHFR | P00374 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TK1 | P04183 | 7/20 | 0.52 |
| ▸ | TK2 | O00142 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9216396 | 1.00 | NT5M (0.59) | NT5MDHFRALDH1A1NPSR1TK1 | |
| SCHEMBL10523447 | 0.85 | TK2 (0.47) | NT5MDHFRALDH1A1NPSR1TK1 | |
| SCHEMBL10523444 | 0.85 | TK2 (0.47) | NT5MDHFRALDH1A1NPSR1TK1 | |
| SCHEMBL2455603 | 0.83 | DHFR (0.67) | NT5MDHFRTK1 | |
| SCHEMBL2511666 | 0.83 | DHFR (0.67) | NT5MDHFRTK1 | |
| SCHEMBL12303789 | 0.83 | DHFR (0.67) | NT5MDHFRTK1 | |
| SCHEMBL31084252 | 0.83 | DHFR (0.67) | NT5MDHFRTK1 | |
| SCHEMBL9222238 | 0.81 | NT5M (0.43) | NT5MDHFRALDH1A1NPSR1 | |
| SCHEMBL22992469 | 0.80 | DHFR (0.60) | NT5MDHFRTK1 | |
| SCHEMBL8962393 | 0.80 | DHFR (0.60) | NT5MDHFRTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315534-B2 | Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315534-B2 | Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-04-19 | — | — | US | disclosed |
| US-20090117041-A1 | Radiologic Agents for Monitoring Alzheimer's Disease Progression and Evaluating a Response to Therapy and Processes for the Preparation of Such Agents | US ARMY, SECRETARY OF THE ARMY | 2009-05-07 | — | — | US | disclosed |
| US-20090117041-A1 | Radiologic Agents for Monitoring Alzheimer's Disease Progression and Evaluating a Response to Therapy and Processes for the Preparation of Such Agents | US ARMY, SECRETARY OF THE ARMY | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117041-A1 | Radiologic Agents for Monitoring Alzheimer's Disease Progression and Evaluating a Response to Therapy and Processes for the Preparation of Such Agents | TYMP, UMPS, TYMS | NT5M 1952/4885DHFR 113/4885ALDH1A1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.